Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / S••

K•••••'s K•••••• (formerly MAP Patient Access) enters German market through acquisition of SKC

Add-on acquisitionclosedadd-onannouncement date unknownFact
What happened
Target
S••
Platform
K••••••add-on basis: The acquisition represents the second move by K••••• backed K•••••• to build a pan-European market access consulting business, following the acquisition of AxTalis in May 2024.
Control
Control
Share acquired
unknown
Industry
business_services / consulting
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
  • K••••••Platformconfirmed
    “The acquisition represents the second move by K••••• backed K•••••• to build a pan-European market access consulting business, following the acquisition of AxTalis in May 2024.”
  • K••••• C•••••• L••Sponsorconfirmed
    “The acquisition represents the second move by K••••• backed K•••••• to build a pan-European market access consulting business, following the acquisition of AxTalis in May 2024.”
  • K•••••Sponsorconfirmed
    “The acquisition represents the second move by K••••• backed K•••••• to build a pan-European market access consulting business, following the acquisition of AxTalis in May 2024.”
Side not stated
  • S••Targetconfirmed
    “K•••••, a leading sector-focused private equity firm, is pleased to announce that K•••••• (formerly MAP Patient Access (“MAP”), a provider of market access consulting services to the biopharma sector, has completed the acquisition of SKC, a Germany-based provider of market access consulting services”
Evidence
“K•••••, a leading sector-focused private equity firm, is pleased to announce that K•••••• (formerly MAP Patient Access (“MAP”), a provider of market access consulting services to the biopharma sector, has completed the acquisition of SKC, a Germany-based provider of market access consulting services.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 18, 2026
K•••••'s K•••••• (formerly MAP Patient Access) enters German market through acquisition of | Private Equity Intelligence | DFX